On the reduced delisting risk of ordinary shares of Sangamo ...

(ISIN US8006771062, hereinafter – Shares, QI) from The NASDAQ Stock Market LLC (hereinafter - Nasdaq). Information on delisting risk of ordinary ...

ITS hereby informs on the reduced delisting risk of ordinary shares of Sangamo Therapeutics, Inc. (ISIN US8006771062, hereinafter – Shares, QI) from The NASDAQ ...

Form 10-Q for Sangamo Therapeutics INC filed 08/06/2024

... common stock may be subject to a delisting action by Nasdaq. A ... stock split given the reduced number of shares of our common stock.

Form 10-Q for Sangamo Therapeutics INC filed 08/08/2023

4. Page 5. Table of Contents. •. If we fail to meet continued listing standards of the Nasdaq Stock Market LLC, our common stock may be delisted ...

Form 8-K for Sangamo Therapeutics INC filed 04/30/2024

The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Select Market. In accordance with Nasdaq ...

Form 10-Q for Sangamo Therapeutics INC filed 11/12/2024

Sangamo's common stock ... our common stock and the market price of our common stock could decrease ... were delisted from Nasdaq, trading of our common stock ...

Document - SEC.gov

(a) The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act. Sangamo has delivered or made available (by filing on the SEC's ...

Form 10-Q for Sangamo Therapeutics INC filed 05/09/2024

Delisting could adversely affect the liquidity of our common stock ... reduced number of shares of our common stock that will be outstanding.

Sangamo Announces Completion Of TxCell Acquisition

TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market. ... ordinary shares of TxCell. Upon completion of ...

Form 10-Q for Sangamo Therapeutics INC filed 11/01/2023

... reduced number of shares of our common stock that will be outstanding ... our common stock is subject to delisting. At that time, we may ...

tm225197-16_424b4 - none - 35.3438454s - SEC.gov

... ordinary shares to decline. If we, for any reason, are unable to obtain or ... decline in patients with IPF and showed a reduced risk of mortality.

Form 8-K for Sangamo Therapeutics INC filed 03/25/2024

... shares of Common Stock is less than the Reported Outstanding Share Number, the ... Common Stock under the Exchange Act or delisting the ...

Filed pursuant to rule 424(b)(4) - TC BioPharm Limited

After any lock up period, a substantial number of our issued and outstanding ordinary shares will be eligible for trading on the public securities market by ...

SEC Filing | Caribou Biosciences, Inc.

Investing in shares of our common stock involves a high degree of risk. You ... shares, could reduce the market price of our common stock. After this ...

Delisting risks for China tech stocks averted as US gets 'historic ...

US regulators have gained full access to the audits of Chinese companies for the first time, reducing the threat that tech giants such as Alibaba (BABA) and JD ...

Sangamo Therapeutics, Inc. Common Stock (SGMO) - Nasdaq

Today's High/Low. $2.54/$2.09. Share Volume. 7,652,523. Average Volume. 5,680,386. Previous Close. $2.44. 52 Week High/Low. $3.179/$0.304. Market Cap.

SANGAMO THERAPEUTICS, INC SEC 10-Q Report - TradingView

Nasdaq Listing Risks: Failure to meet the listing standards of the Nasdaq Stock Market LLC could result in the delisting of common stock, ...

Immatics NV

Investing in our securities involves a high degree of risk. Before buying any securities ... ordinary shares could decline and you could lose some or all of your ...

SECURITIES AND EXCHANGE COMMISSION FORM 20-F uniQure ...

... reduced disclosure requirements applicable to emerging growth ... Company—Risk Factors—Risks Related to our Ordinary Shares—If we fail ...

Sangamo Announces Completion of TxCell Acquisition

... Sangamo and has been delisted from the French stock market. ... ordinary shares of TxCell. Upon completion of the ... reduce the risk of unnecessary ...